Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Peking University Cancer Hospital, Beijing, China

Survival: 14.0 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: China
City/State/Province: Beijing
Hospital: Peking University Cancer Hospital
Journal: Link
Date: 6/2011

This study involved 43 patients with metastatic melanoma. Patients had a median age of 57 years and 46.5% were male.

Patients were treated with the biologic therapy called imatinib mesylate, which is a tyrosine kinase inhibitor.

The maximum toxicity reported was grade 4, including 1 case each of neutropenia and psychiatric symptoms and 2 cases of increased liver enzymes (AST/ALT). Grade 3 fatigue, anorexia, nausea, vomiting, and rash were also reported.

The median progression-free survival and median overall survival was 3.5 and 14.0 months, respectively.

This study was partially supported by Novartis Oncology in China.

Correspondence: Dr. Jun Guo; email:

E-mail to a Friend Email Physician More Information